Eupraxia Pharmaceuticals Inc. (EPRX) – What Are Brokerages Thinking About This Stock?

Posted by Geri Gentry on Nov 11th, 2026

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $17.17.

Several equities analysts have recently weighed in on EPRX shares. Wedbush started coverage on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price objective on the stock. Oppenheimer reissued an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, October 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st.

View Our Latest Analysis on EPRX

Eupraxia Pharmaceuticals Price Performance

Shares of Eupraxia Pharmaceuticals stock opened at $7.63 on Wednesday. The business’s fifty day moving average price is $7.58 and its 200 day moving average price is $7.25. Eupraxia Pharmaceuticals has a twelve month low of $5.63 and a twelve month high of $9.32. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $513.04 million, a P/E ratio of -7.48 and a beta of 1.04.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.03. As a group, research analysts anticipate that Eupraxia Pharmaceuticals will post -0.90 earnings per share for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Seven Fleet Capital Management LP acquired a new position in shares of Eupraxia Pharmaceuticals during the 1st quarter valued at $5,137,000. Redmile Group LLC acquired a new stake in Eupraxia Pharmaceuticals in the 1st quarter valued at $5,068,000. Rubric Capital Management LP acquired a new stake in Eupraxia Pharmaceuticals in the 1st quarter valued at $5,004,000. Cibc World Market Inc. acquired a new stake in Eupraxia Pharmaceuticals in the 2nd quarter valued at $1,539,000. Finally, Bank of America Corp DE purchased a new position in Eupraxia Pharmaceuticals in the second quarter valued at about $1,750,000.

Key Stories Impacting Eupraxia Pharmaceuticals

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

Positive Sentiment: Eupraxia reported a third-quarter 2026 loss of $0.23 per share, narrower than the $0.26 loss analysts expected. The earnings beat may be encouraging, although the company remains loss-making. Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Positive Sentiment: RBC Capital initiated coverage with an Outperform rating and a $14 price target, while flagging the stock as speculative risk. The rating signals analyst optimism, balanced by the high-risk designation. RBC Capital Starts Eupraxia Pharmaceuticals at Outperform
Negative Sentiment: The company established a $125 million at-the-market offering program, allowing it to sell shares over time. The financing provides access to capital but could dilute existing shareholders if shares are issued. Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability. Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.